ArticleThe Journal of biological chemistry2025
Prolintane analogs as hybrid monoamine transporter ligands: Structural determinants and species differences.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Prolintane is a synthetic stimulant that acts by inhibiting the uptake of dopamine and norepinephrine into neurons. Initially prescribed for attention deficit hyperactivity disorder and narcolepsy, its medical use was discontinued due to concerns about abuse liability. Here, we explored structure-activity relationships for novel fluoro and methyl-ring-substituted prolintanes synthesized via a modified one-pot Mannich Barbier reaction. Radiotracer flux assays in transfected human embryonic kidney 293 (HEK293) cells and rat brain synaptosomes revealed that prolintane analogs display potent uptake inhibition at the dopamine transporter (DAT) and norepinephrine transporter (NET), with weaker effects at the serotonin transporter (SERT). Across all compounds, SERT inhibitory potencies were at least 10-fold weaker at human SERT (hSERT) compared to rat SERT (rSERT). Methyl substitution at the 2-, 3-, or 4-ring position enhanced SERT inhibition potency relative to DAT, lowering the DAT/SERT ratio and suggesting reduced abuse liability. Fluorine substitution also enhanced SERT potency relative to DAT, however, to a lesser extent. Interestingly, prolintane and its analogs induced hSERT-mediated ionic currents and [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.